Bipolar Disorder: Microdosing Psilocybin to Lessen Depressive Symptoms

Abstract

Research on microdosing psilocybin as a novel treatment option for bipolar depression is still in its infancy; however, new research studies show significant improvement in major depression and treatment-resistant depression after a one-time large dose of psilocybin. The purpose of this systematic literature review was to evaluate recent studies on psilocybin and the reduction of depressive symptoms in participants with treatment-resistant depression or major depression, as well as the benefits of microdosing psilocybin. A total of seven studies met the criteria for statistical data, population characteristics, and the use of psilocybin for depression. One study examined the benefits versus challenges of microdosing psilocybin recreationally along with depression screening via online self-reporting questionnaires and DAS-A-17 scale. The additional six studies evaluated the effects of psilocybin on depression, anxiety, and mood disturbances. Quantitative results indicate that psilocybin can significantly reduce depressive symptomatology in treatment-resistant depression, along with anxiety, neuroticism, anhedonia, anger and hostility, and impulsiveness. Results also found an increase in joy, awe, the feeling of love, and positive emotions. The researcher discussed the strengths, limitations, and suggestions for future research. Further studies with more rigorous analysis, larger and more inclusive sample sizes, and increased double-blind and controlled designs would be necessary to understand treatment options involving psilocybin for depression.

Description

Keywords

Psilocybin, Bipolar II Disorder, Depression, Microdosing, Serotonin Agonist

Citation

DOI